Clinical Trial Update: Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating regulatory T cells for ARDS associated with COVID-19; study terminated with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Tregs therapy (regARDS)

Snippet

Sponsor: Jeffrey Bluestone | Conditions: Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV | Phase 1 | Status: TERMINATED | Results posted: 2023-06-05